FDA Grants First Full Approval for Potassium Bromide Chewable Tablets to Treat Canine Idiopathic Epilepsy
Key Insights
The U.S. Food and Drug Administration (search) has granted full approval to KBroVet (search) (potassium bromide chewable tablets) for controlling seizures (search) in dogs with idiopathic epilepsy (search), marking the first FDA-approved medication specifically for this condition.
KBroVet (search) is administered once daily as a chewable tablet and requires prescription-only access due to the need for professional veterinary monitoring and management of potential adverse effects.
Dogs receiving potassium bromide therapy require careful monitoring to prevent bromide intoxication (search) and must maintain consistent diets, as dietary changes can affect seizure control or increase toxicity risk.
The U.S. Food and Drug Administration (search) has granted full approval to PRN Pharmacal (search)'s KBroVet (search) (potassium bromide chewable tablets) for the control of seizures (search) in dogs diagnosed with idiopathic epilepsy (search), marking the first FDA-approved medication specifically for this condition. The approval was announced by the FDA's Center for Veterinary Medicine (CVM) and represents an important milestone for veterinarians and pet owners managing this challenging neurologic disorder.
First FDA-Approved Treatment for Canine Idiopathic Epilepsy
While potassium bromide has been used for decades as an anticonvulsant in dogs, particularly as adjunct therapy for patients who do not achieve adequate seizure control with phenobarbital alone, KBroVet (search) is now the first potassium bromide product to receive full FDA approval specifically for dogs with idiopathic epilepsy (search). Idiopathic epilepsy is a seizure disorder with no identifiable underlying cause and is one of the most common chronic neurologic conditions seen in dogs.
KBroVet (search) is formulated as a once-daily, orally administered chewable tablet designed to help control seizures (search) associated with idiopathic epilepsy (search). The medication is available by prescription only due to the professional veterinary expertise required to diagnose idiopathic epilepsy and monitor safe use of the product, including treatment of any adverse reactions. The chewable formulation may help improve compliance, especially for dogs that are difficult to medicate.
Critical Monitoring Requirements
The FDA emphasizes that dogs receiving potassium bromide must be carefully monitored to reduce the risk of bromide intoxication (search), a condition that occurs when bromide levels become too high and overwhelm the nervous system. Because potassium bromide has a long half-life, toxicity can develop gradually, making routine monitoring and client education essential.
Clinical signs of severe bromide intoxication (search) include depression or lethargy, behavioral changes, poor coordination (ataxia), weakness or partial loss of voluntary movement in the hind limbs, dilated pupils, and in extreme cases, stupor or coma.
Dietary Considerations
One of the most important aspects of potassium bromide therapy is maintaining diet consistency. Chloride levels in the diet directly affect bromide concentrations in the body, and abrupt diet changes, such as switching foods, adding treats, or changing sodium content, can either reduce seizure control or increase the risk of toxicity. Pet owners must consult their veterinarian before making any dietary changes for dogs receiving potassium bromide.
Significance for Veterinary Medicine
The FDA's full approval of KBroVet (search) reinforces the importance of evidence-based therapies in veterinary medicine and provides clinicians with an FDA-approved option for long-term seizure management in dogs with idiopathic epilepsy (search). Managing idiopathic epilepsy often requires long-term medication, close monitoring, and strong collaboration between veterinarians and pet owners.
For pet owners, the approval underscores the need for partnership with their veterinarian, as epilepsy management involves ongoing observation, communication, and care beyond simply administering medication. The approval represents meaningful progress for dogs living with epilepsy and advances in veterinary neurology research and pharmaceutical development.